logo.jpg
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
26 mars 2020 06h00 HE | ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors -- Marseille, France, March 26, 2020 –...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
30 janv. 2020 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Enrolment of first p
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
27 janv. 2020 01h30 HE | Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
Breakthrough Surgica
Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Colorectal Surgery
03 janv. 2017 09h15 HE | Cohera Medical, Inc.
Cohera Medical, Inc.® Enrolls First Patient in Clinical Trial of its Sylys® Surgical Sealant in the U.S. RALEIGH, N.C., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator...